Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Drug Levels Associated with Optimal Discrimination Between Remission and Non-Remission and Comparison of Antibody Assays During First Year of Stable Infliximab Maintenance Therapy in Inflammatory Bowel Disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Effects of stratified medication review in high-risk patients at admission to hospital: a randomised controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Qualitative exploration of practices to prevent medication errors in neonatal intensive care units: a focus group study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Medication-overuse headache: a perspective review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Life-threatening viral disease in a novel form of autosomal recessive IFNAR2 deficiency in the Arctic

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Circadian rhythm of markers of bone turnover in patients with chronic kidney disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Reply

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  4. Praktisk anvendelse af thiopuriner hos patienter med kronisk inflammatoriske tarmsygdomme

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

BACKGROUND: To implement therapeutic drug monitoring-based strategies for infliximab (IFX) in inflammatory bowel disease, the authors assessed IFX levels for optimal discrimination between remission and nonremission and compared assays for anti-IFX antibodies (Abs).

METHODS: The retrospective cohort comprised 163 bionaive patients with inflammatory bowel disease who received stable IFX maintenance therapy (5 mg/kg every 8 weeks [q8w]) for 1 year. The clinical and biochemical remission status was assessed at all infusions (weeks 14-22-30-38-46-54), and IFX and anti-IFX Abs were estimated using a time-resolved fluorometric assay (n = 690; 88% of infusions). Samples positive for anti-IFX Abs or IFX levels < limit of detection (n = 102) were analyzed by 2 binding assays [enzyme-linked immunosorbent assay (ELISA)] and functional reporter gene assay/drug-tolerant enzyme immunoassay.

RESULTS: At all assessed time points, IFX levels were more than double in patients presenting clinical or biochemical remission. An IFX concentration of 4.5 mcg/mL was associated with clinical remission during the entire first year of therapy [sensitivity 54% (49-59), specificity 73% (67-78), AUCROC 0.65 (0.60-0.69), P < 0.0001]; these values were comparable with biochemical remission. Exploratory assessments for endoscopic remission (n = 131) were performed at the discretion of the treating physician. Anti-IFX Abs were associated with undetectable IFX and treatment failure [OR 2.9 (1.4-6.0), P < 0.01], irrespective of persistency or transiency. All performed assays detected anti-IFX Abs were picked up by all assays in ∼2/3 of samples. Binding assays demonstrated a higher sensitivity to anti-IFX Abs.

CONCLUSIONS: IFX at ∼5 mcg/mL was associated with clinical and biochemical remission during the first year of maintenance therapy. During this phase of therapy, standard binding assays are appropriate for therapeutic drug monitoring.

OriginalsprogEngelsk
TidsskriftTherapeutic Drug Monitoring
Vol/bind44
Udgave nummer2
Sider (fra-til)290-300
Antal sider11
ISSN0163-4356
DOI
StatusUdgivet - 1 apr. 2022

Bibliografisk note

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

ID: 69749567